The selective β 1-adrenoceptor antagonist nebivolol is a potential oestrogen receptor agonist with neuroprotective abilities

British Journal of Pharmacology

Volumn 159, Issue 6, 2010, Pages 1264-1273

  Manthey, D ^a   Gamerdinger, M ^a   Behl, C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Neuroprotection; Oestrogen receptors; Oxidative stress; Selective oestrogen receptor modulator

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GAMMA SECRETASE; HYDROGEN PEROXIDE; NEBIVOLOL; PARAQUAT; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; FIREFLY LUCIFERASE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; PROTEIN BINDING; TUMOR CELL LINE;

ADRENERGIC BETA-ANTAGONISTS; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BENZOPYRANS; CELL LINE, TUMOR; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHANOLAMINES; HUMANS; LUCIFERASES, FIREFLY; MICE; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-1; TRANSFECTION;

EID: 77949418836     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00610.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S.-I. et al. (2003). Putative function of ADAM9, ADAM10, and ADAM17 as APP [alpha]-secretase. Biochem Biophys Res Commun 301: 231-235.
3. Behl C (2002). Ooestrogen as a neuroprotective hormone. Nat Rev Neurosci 3: 433-442.
4. Behl C, Manthey D (2000). Neuroprotective activities of oestrogen: an update. J Neurocytol 29: 351-358.
5. Behl C, Widmann M, Trapp T, Holsboer F (1995). 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 216: 473-482.
6. Behl C, Skutella T, Lezoualc'h F, Post A,Widmann M, Newton CJ et al. (1997). Neuroprotection against oxidative stress by estrogens: structure-activity relationships. Mol Pharm 51: 535-541.
7. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM (2007). Neurotrophic and neuroprotective actions of oestrogen: basic mechanisms and clinical implications. Steroids 72: 381-405.
8. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, Van Gorsel E, Heemskerk JW et al. (2000). Nebivolol: a third-generation betablocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 102: 677-684.
9. Brown AM, Jeltsch JM, Roberts M, Chambon P (1984). Activation of pS2 gene transcription is a primary response to oestrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 81: 6344-6348.
10. Cardona-Gomez GP, Mendez P, Doncarlos LL, Azcoitia I, Garcia-Segura LM (2001). Interactions of oestrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res Brain Res Rev 37: 320-334.
11. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006). Impact of oestrogen receptor beta on gene networks regulated by oestrogen receptor alpha in breast cancer cells. Endocrinology 147: 4831-4842.
12. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J et al. (2002). Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, oestrogen receptor. Circ Res 90: 413-419.
13. De Groot AA, Mathy MJ, Van Zwieten PA, Peters SL (2004). Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 43: 148-153.
14. De Nigris F, Mancini FP, Balestrieri ML, Byrns R, Fiorito C, Williams-Ignarro S et al. (2008). Therapeutic dose of nebivolol, a nitric oxide-releasing [beta]-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide 19: 57-63.
15. De Strooper B, Annaert W (2000). Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113 (Pt 11): 1857-1870.
16. Deuss M, Reiss K, Hartmann D (2008). Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5: 187-201.
17. Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, Naslund J (2003). Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem 278: 24277-24284.
18. Garban HJ, Buga GM, Ignarro LJ (2004). Oestrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 43: 638-644.
19. Garbin U, Fratta Pasini A, Stranieri C, Manfro S, Mozzini C, Boccioletti V et al. (2008). Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm 2008: 367590.
20. Garcia-Segura LM, Azcoitia I, Doncarlos LL (2001). Neuroprotection by estradiol. Prog Neurobiol 63: 29-60.
21. Gelinas S, Bureau G, Valastro B, Massicotte G, Cicchetti F, Chiasson K et al. (2004). Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress. Neurotox Res 6: 141-148.
22. Grundt C, Meier K, Grundt A, Lemmer B (2007). Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001-1007.
23. Harms C, Lautenschlager M, Bergk A, Katchanov J, Freyer D, Kapinya K et al. (2001). Differential mechanisms of neuroprotection by 17 beta-estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 21: 2600-2609.
24. Janssen PM, Zeitz O, Rahman A, Hasenfuss G (2001). Protective role of nebivolol in hydroxyl radical induced injury. J Cardiovasc Pharmacol 38 (Suppl. 3): S17-23.
25. Maggi A, Ciana P, Belcredito S, Vegeto E (2004). Oestrogens in the nervous system: mechanisms and nonreproductive functions. Annu Rev Physiol 66: 291-313.
26. Manthey D, Behl C (2006). From structural biochemistry to expression profiling: neuroprotective activities of oestrogen. Neuroscience 138: 845-850.
27. Manthey D, Heck S, Engert S, Behl C (2001). Oestrogen induces a rapid secretion of amyloid beta precursor protein via the mitogenactivated protein kinase pathway. Eur J Biochem 268: 4285-4291.
28. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T (2006). Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 48: 862-869.
29. McEwen BS (2001). Invited review: oestrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 91: 2785-2801.
30. Mendez P, Azcoitia I, Garcia-Segura LM (2005). Interdependence of ooestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms. J Endocrinol 185: 11-17.
31. Miller NR, Jover T, Cohen HW, Zukin RS, Etgen AM (2005). Oestrogen can act via oestrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death. Endocrinology 146: 3070-3079.
32. Moosmann B, Behl C (1999). The antioxidant neuroprotective effects of oestrogens and phenolic compounds are independent from their oestrogenic properties. Proc Natl Acad Sci USA 96: 8867-8872.
33. Nuedling S, Kahlert S, Loebbert K, Doevendans PA, Meyer R, Vetter H et al. (1999). 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res 43: 666-674.
34. O'Lone R, Frith MC, Karlsson EK, Hansen U (2004). Genomic targets of nuclear oestrogen receptors. Mol Endocrinol 18: 1859-1875.
35. Pfaffl MW, Horgan GW, Dempfle L (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
36. Pietrzik C, Behl C (2005). Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol 86: 173-185.
37. Singer CA, Rogers KL, Strickland TM, Dorsa DM (1996). Oestrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 212: 13-16.
38. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA et al. (2002). PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 3: 780-786.
39. Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996). Metabolism of the 'Swedish' amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the 'beta-secretase' site occurs in the golgi apparatus. J Biol Chem 271: 9390-9397.
40. Thomson AJ, Telfer JF, Kohnen G, Young A, Cameron IT, Greer IA et al. (1997). Nitric oxide synthase activity and localization do not change in uterus and placenta during human parturition. Hum Reprod 12: 2546-2552.
41. Toker S, Toker A, Gulcan E, Gulcan A (2008). Nebivolol may be beneficial via nitric oxide on osteoporosis treatment. Bone 42: S89.
42. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC (2000). Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 50: 377-379.
43. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM (2006). Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. 10.1210/er.2005-0020. Endocr Rev 27: 575-605.
44. Van Bortel LM, Fici F, Mascagni F (2008). Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a metaanalysis. Am J Cardiovasc Drugs 8: 35-44.
45. Van De Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H et al. (1988). Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 11: 552-563.
46. Wagenfeld L, Himpel O, Galambos P, Matthiesen N, Wiermann A, Richard G et al. (2008). Protective effects of nebivolol on oxygen free radical-induced vasoconstrictions in vitro. Med Sci Monit 14: BR109-BR112.
47. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L et al. (1998). Oestrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 4: 447-451.
48. Yang W.-L., Sun AY (1998). Paraquat-induced cell death in PC12 cells. Neurochem Res 23: 1387-1394.
49. Yeh S, Chang C (1996). Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93: 5517-5521.
50. Zschocke J, Manthey D, Bayatti N, Behl C (2003). Functional interaction of oestrogen receptor alpha and caveolin isoforms in neuronal SK-N-MC cells. J Steroid Biochem Mol Biol 84: 167-170.
51. Zschocke J, Manthey D, Bayatti N, Van Der Burg B, Goodenough S, Behl C (2002). Oestrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells. J Biol Chem 277: 38772-38780.